Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Falagas, M. E. Articles by Michalopoulos, A. Search for Related Content PubMed PubMed Citation Articles by Falagas, M. E. Articles by Michalopoulos, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2006, p. 2541-2543, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00224-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Risk Factors for Isolation of Strains Susceptible Only to Polymyxin among Patients with Pseudomonas aeruginosa Bacteremia

Matthew E. Falagas,^1,2,3* Patra K. Koletsi,¹ Petros Kopterides,^1,4 and Argyris Michalopoulos^1,5

Alfa Institute of Biomedical Sciences, Athens, Greece,¹ Department of Medicine, Henry Dunant Hospital, Athens, Greece,² Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts,³ Critical Care Department, Attikon University Hospital, Athens, Greece,⁴ Intensive Care Unit, Henry Dunant Hospital, Athens, Greece⁵

Received 21 February 2006/ Returned for modification 20 March 2006/ Accepted 10 April 2006

Top Abstract Text References

 
We conducted a case-control study to identify risk factors associated with the isolation of Pseudomonas aeruginosa strains susceptible only to polymyxin from blood by comparing data between 16 patients with blood isolates that were susceptible only to polymyxins and 40 patients with blood isolates that were susceptible to carbapenems. The multivariable analysis showed that exposure to carbapenems was associated with the development of P. aeruginosa bacteremia susceptible only to polymyxin (odds ratio, 9.0; 95% confidence interval, 2.4 to 34.3; P = 0.001).

Top Abstract Text References

 
Pseudomonas aeruginosa is an important nosocomial pathogen that causes a wide spectrum of infections and leads to substantial morbidity and mortality (4, 8). Unfortunately, P. aeruginosa has intrinsic resistance to multiple antimicrobial agents, and the emergence of resistance during therapy is a frequently described phenomenon (8). The continuously evolving antimicrobial resistance of P. aeruginosa isolates has led to the recognition of an alarming epidemic of infections due to P. aeruginosa that is susceptible only to polymyxin (1, 3). However, to our knowledge, no study so far has focused on the analysis of risk factors for the development of infections caused by P. aeruginosa isolates susceptible only to polymyxin.

A retrospective case-control study of all patients with bacteremia due to P. aeruginosa during the period between 1 January 2002 and 31 August 2005 was conducted at the Henry Dunant Hospital, a 450-bed tertiary care center in Athens, Greece. The Institutional Review Board of the hospital approved the study. The computerized database of the hospital's bacteriology laboratory was used to identify these patients. For patients with more than one episode of bacteremia due to P. aeruginosa, only data relevant to the first episode were collected and analyzed. Exposure to a specific antimicrobial agent was considered significant enough to be included in our analysis if (i) exposure had occurred only during the hospitalization in which the bacteremia developed and (ii) the antibiotic had been administered for at least three consecutive days prior to the development of bacteremia.

Identification and susceptibility testing of the P. aeruginosa isolates were performed by using an automated broth microdilution method (Vitek II; bioMérieux, Hazelwood, MO). The breakpoints used for the in vitro susceptibility of the P. aeruginosa blood isolates were those defined by the Clinical and Laboratory Standards Institute (CLSI). Susceptibility to colistin sulfate was tested by means of the E test (AB Biodisk, Solna, Sweden) (isolates were considered susceptible if the MIC was <2 µg/ml) as well as the disk diffusion method with the use of a l0-µg colistin disk (Oxoid, Basingstoke, Hants, England). Isolates were considered susceptible if the inhibition zone was more than or equal to 11 mm and resistant if the inhibition zone was less than or equal to 8 mm. Intermediate sensitivity to a specific antibiotic was considered as resistance, which reflects clinical practice.

Categorical variables were compared by means of ² or Fisher's exact test. For continuous variables, we used the Student's t test or the Mann-Whitney test for normally and nonnormally distributed variables, respectively. All variables associated with the development of P. aeruginosa bacteremia caused by strains susceptible only to polymyxin that were significant (P < 0.05) in the univariate analysis were included in a backward, stepwise, multivariable logistic regression model. All statistical analyses were performed using SPSS 11.0 (SPSS Inc., Chicago, IL) and S-PLUS 6.1 Professional (Insightful Corporation, Seattle, WA).

There were 70 patients with bacteremia due to P. aeruginosa during the study period. We focused our analysis on the comparison of exposure to various risk factors between patients with P. aeruginosa blood isolates that were susceptible only to polymyxin and those with P. aeruginosa blood isolates susceptible to at least polymyxins and carbapenems. Thus, we excluded 12 patients with bacteremia due to P. aeruginosa strains susceptible to both polymyxins and piperacillin/tazobactan (resistant to carbapenems) and 2 patients with bacteremia due to P. aeruginosa strains susceptible to polymyxins and aminoglycosides (resistant to carbapenems) from our analysis. Subsequently, there were 56 patients with bacteremia secondary to P. aeruginosa (40 intensive care unit [ICU] patients and 16 ward patients) available for inclusion in our analysis. In 16 of these patients, the isolate was susceptible only to polymyxin (28.6%), and in 40 patients (71.4%), the isolate remained susceptible to carbapenems; susceptibility to ertapenem was not tested.

Among patients with bacteremia due to P. aeruginosa strains that were susceptible only to polymyxin, pneumonia was the predominant infection (37.5% [6/16]), followed by urinary tract infection (18.8% [3/16]), intra-abdominal infection (12.5% [2/16]), and catheter-related infection (6.3% [1/16]). In 4 out of the 16 remaining cases (25%), the origin of the bacteremia was not clear. Among patients with bacteremia due to P aeruginosa isolates that were susceptible to carbapenems, pneumonia was again the predominant infection (45% [18/40]), followed by urinary tract infection (12.5% [5/40]) and intra-abdominal infection (5% [2/40]). Fifteen of the 40 cases (37.5%) of bacteremia were not associated with any identifiable site.

Mortality was 62.5% for patients with bacteremia due to P. aeruginosa blood isolates that were susceptible only to polymyxin and 37.5% for patients with bacteremia due to isolates susceptible to carbapenems (P = 0.09). In Table 1, we summarize the results of the univariable analysis showing that exposure to quinolones, metronidazole, glycopeptides, and carbapenems as well as admission to an ICU, tracheotomy, parenteral feeding, and glucocorticoid treatment were associated with isolation of a strain susceptible only to polymyxin among patients with P. aeruginosa bacteremia. The backward, stepwise, multivariable logistic regression model revealed that the only significant risk factor was prior use of carbapenems (odds ratio, 9.0; 95% confidence interval, 2.4 to 34.3; P = 0.001).

View this table: [in this window] [in a new window]

TABLE 1. Univariate analysis of risk factors associated with bacteremia caused by P. aeruginosa isolates susceptible only to polymyxin

The rapid emergence of imipenem resistance among susceptible P. aeruginosa strains is well known and adds credibility to our findings. Moreover, mutational overexpression of P. aeruginosa genes associated with multidrug efflux systems has been shown to promote acquired multidrug resistance (7). Thus, we can hypothesize that in some settings, carbapenem use per se can induce the spread of multidrug-resistant P. aeruginosa even without prior use of other classes of antibiotics. Our study implies that a similar scenario may be possible in the emerging epidemic of infection by P. aeruginosa that is susceptible only to polymyxin.

Our study has several limitations. It is a small, retrospective, case-control study with all the inherent problems related to this study design (2). Also, the fact that our control group consisted of patients with carbapenem-susceptible strains may have led us to overestimate the odds ratio for carbapenem use as a risk factor for the acquisition of strains susceptible only to polymyxin (5, 6). In addition, we excluded patients with isolates susceptible to polymyxins and antibiotics of other classes but resistant to carbapenems from our analysis because we wanted to focus on a direct comparison between blood isolates susceptible only to polymyxin and those susceptible to carbapenem. Also, we did not screen our patients for the presence of P. aeruginosa by active surveillance culture and did not perform molecular epidemiologic analysis. Thus, it is not possible to distinguish whether a particular case was due to newly acquired resistance of a previously susceptible strain or due to horizontal transmission of a resistant strain. Finally, we did not examine the effect of various pharmacokinetic and pharmacodynamic parameters of carbapenem administration, such as insufficient dosing, dosing interval, and duration of infusion, on the development of antimicrobial resistance.

In conclusion, despite the previously mentioned limitations, our study provides insight into the rising problem of bacteremia caused by strains of P. aeruginosa that are susceptible only to polymyxin by highlighting prior carbapenem use as an independent risk factor for its development.

 
The study was conducted at the Henry Dunant Hospital, Athens, Greece.

 
* Corresponding author. Mailing address: Alfa Institute of Biomedical Sciences, 9 Neapoleos Str., 151 23 Marousi, Greece. Phone: 30-694-611.0000. Fax: 30-210-683.9605. E-mail: m.falagas{at}aibs.gr.

Top Abstract Text References

 

1
1. Bratu, S., J. Quale, S. Cebular, R. Heddurshetti, and D. Landman. 2005. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur. J. Clin. Microbiol. Infect. Dis. 24:196-201.[CrossRef][Medline]
2
2. D'Agata, E. M. 2005. Methodologic issues of case-control studies: a review of established and newly recognized limitations. Infect. Control Hosp. Epidemiol. 26:338-341.[Medline]
3
3. Deplano, A., O. Denis, L. Poirel, D. Hocquet, C. Nonhoff, B. Byl, P. Nordmann, J. L. Vincent, and M. J. Struelens. 2005. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 43:1198-1204.[Abstract/Free Full Text]
4
4. Gaynes, R., J. R. Edwards, and the National Nosocomial Infections Surveillance System. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.[CrossRef][Medline]
5
5. Harris, A. D., T. B. Karchmer, Y. Carmeli, and M. H. Samore. 2001. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis. 32:1055-1061.[CrossRef][Medline]
6
6. Harris, A. D., M. H. Samore, M. Lipsitch, K. S. Kaye, E. Perencevich, and Y. Carmeli. 2002. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin. Infect. Dis. 34:1558-1563.[CrossRef][Medline]
7
7. Poole, K. 2001. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J. Mol. Microbiol. Biotechnol. 3:255-264.[Medline]
8
8. Rossolini, G. M., and E. Mantengoli. 2005. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin. Microbiol. Infect. 11:17-32.

---

Antimicrobial Agents and Chemotherapy, July 2006, p. 2541-2543, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00224-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Falagas, M. E. Articles by Michalopoulos, A. Search for Related Content PubMed PubMed Citation Articles by Falagas, M. E. Articles by Michalopoulos, A.